Optimization of anticoagulation with warfarin for stroke prevention: Pharmacogenetic considerations

American Journal of Therapeutics

Volumn 18, Issue 3, 2011, Pages

  Tomek, Ales ^a,b   Matoska, Vaclav ^b   Eisert, Christian ^c   Serebruany, Victor L ^c,d  

^a CHARLES UNIVERSITY   (Czech Republic)

^b NA HOMOLCE HOSPITAL   (Czech Republic)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Osler Medical Center   (United States)

Author keywords

pharmacogenetics; stroke prevention; Warfarin

Indexed keywords

APOLIPOPROTEIN E; BLOOD CLOTTING FACTOR 7; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 4F2; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE 1; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHEMOPROPHYLAXIS; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; ETHNIC DIFFERENCE; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; PHARMACOGENETICS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; STROKE PATIENT;

ANTICOAGULANTS; ATRIAL FIBRILLATION; FIBRINOLYTIC AGENTS; GENOTYPE; HEMORRHAGE; HUMANS; PHARMACOGENETICS; RISK; STROKE; WARFARIN;

EID: 79958053677     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181cea0cd     Document Type: Article

References (57)

1. Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2008;39:1647-1652.
2. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25: 457-507.
3. Stam J, de Bruijn SSFTM, deVeber G. Anticoagulation for cerebral sinus thrombosis. Cochrane Database Syst Rev. 2002;4:CD002005.
4. Hart R, Pearce L, Aguilar M. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146: 857-867. (Pubitemid 351650486)
5. Hankey GJ, Warlow CP. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet. 1999;354:1457-1463. (Pubitemid 29494766)
6. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360:753-764.
7. Wadelius M, Chen L, Lindh J, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. 2009;113:784-792.
8. Rieder M, Reiner A, Gage B, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352:2285-2293. (Pubitemid 40740552)
9. Perini J, Struchiner C, Silva-Assuncxão E, et al. Pharmacogenetics of warfarin: development of a dosing algorithm for Brazilian patients. Clin Pharmacol Ther. 2008;84:722-728.
10. Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet. 2007;121:23-34. (Pubitemid 46421137)
11. McDonald M, Rieder M, Nakano M, et al. CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol. 2009;75:1337-1346.
12. Takeuchi F, McGinnis R, Bourgeois S, et al. A genomewide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009;5:e1000433.
13. Borgiani P, Ciccacci C, Forte V, et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics. 2009;10:261-266.
14. Rieder M, Reiner A, Rettie A. g-Glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J Thromb Hemost. 2007;5: 2227-2234. (Pubitemid 47617875)
15. Kimmel SE, Christie J, Kealey C, et al. Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J. 2008;8:53-60.
16. Wang T, Li H, TjongW, et al. Genetic factors contribute to patient-specific warfarin dose for Han Chinese. Clin Chim Acta. 2008;396:76-79.
17. Higashi M, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulationrelated outcomes during warfarin therapy. JAMA. 2002; 287:1690-1698. (Pubitemid 34289221)
18. Joffe H, Xu R, Johnson F, et al. Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost. 2004;91:1123-1128. (Pubitemid 38821268)
19. Meckley L, Wittkowsky A, Rieder M, et al. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin patients. Thromb Haemost. 2008;100:229-239.
20. Aithal G, Day C, Kesteven P, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353:717-719. (Pubitemid 29103806)
21. Margaglione M, Colaizzo D, D'Andrea G, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost. 2000;84:775-778.
22. Sanderson S, Emery J, Higgins J. References Cyp2c9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and metaanalysis. Genet Med. 2005;7:97-104. (Pubitemid 40261834)
23. Sconce E, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106: 2329-2333. (Pubitemid 41510803)
24. Veenstra D, Blough DK, Higashi MK, et al. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin Pharmacol Ther. 2005;77:353-364. (Pubitemid 40719264)
25. Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005;5:262-270. (Pubitemid 41131718)
26. Schwarz U, Ritchie M, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008;358:999-1008. (Pubitemid 351347099)
27. Limdi NA, McGwin G, Goldstein J, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther. 2008;83:312-321.
28. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004;427:537-541. (Pubitemid 38209110)
29. Oldenburg J, Bevans CG, Fregin A, et al. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost. 2007;98:570-578. (Pubitemid 47421551)
30. Linder M, Looney S, Adams J, et al. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J Thromb Thrombolysis. 2002;14:227-232. (Pubitemid 37069306)
31. Lyon E, McMillin G, Melis R. Pharmacogenetic testing for warfarin sensitivity. Clin Lab Med. 2008;28:525-537.
32. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th ed. Chest. 2008;133:S160-S198.
33. Kovacs MJ, Cruickshank M, Wells PS, et al. Randomized assessment of a warfarin nomogram for initial oral anticoagulation after venous thromboembolic disease. Haemostasis. 1998;28:62-69. (Pubitemid 29152086)
34. Fennerty A, Dolben J, Thomas P, et al. Flexible induction dose regimen for warfarin and prediction of maintenance dose. BMJ. 1984;288:1268-1270. (Pubitemid 14117132)
35. Shine D, Patel J, Kumar J, et al. A randomized trial of initial warfarin dosing based on simple clinical criteria. Thromb Haemost. 2003;89:297-304. (Pubitemid 36227282)
36. Carlquist JF, Horne BD, Muhlestein JB, et al. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis. 2006;22:191-197. (Pubitemid 44857780)
37. Anderson J, Horne B, Stevens S, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007; 116:2563-2570. (Pubitemid 350179221)
38. Gage BF, Eby C, Milligan PE, et al. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost. 2004;91:87-94. (Pubitemid 38111225)
39. Gage B, Eby C, Johnson J, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84:326-331.
40. Hillman MA, Wilke RA, Caldwell MD, et al. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics. 2004;14:539-547. (Pubitemid 39100005)
41. Tham LS, Nafziger A, Guo J, et al. A warfarin-dosing model inAsians thatuses single-nucleotidepolymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther. 2006;80:346-355. (Pubitemid 44479750)
42. Miao L, Yang J, Huang C, et al. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol. 2007;63:1135-1141. (Pubitemid 350112769)
43. Schelleman H, Chen J, Chen Z, et al. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther. 2008;84:332-339.
44. Huang S, Chen H, Wang X, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics. 2009;19:226-234.
45. Millican E, Lenzini P, Milligan P, et al. Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood. 2007;110:1511-1515. (Pubitemid 47443966)
46. Michaud V, Vanier MC, Brouillette D, et al. Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients. Clin Pharmacol Ther. 2008;83:740-748. (Pubitemid 351556023)
47. Hillman M, Wilke R, Yale S, et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res. 2005;3:137-145.
48. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotypeguided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther. 2008;83: 460-470. (Pubitemid 351272635)
49. Kimura R, Miyashita K, Kokubo Y, et al. Genotypes of vitamin K epoxide reductase, g-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res. 2007;120: 181-186. (Pubitemid 46754413)
50. Salas M, In't Veld BA, van der Linden PD, et al. Impaired cognitive function and compliance with antihypertensive drugs in elderly: the Rotterdam study. Clin Pharmacol Ther. 2001;70:561-566. (Pubitemid 34008414)
51. Cruess DG, Localio AR, Platt AB, et al. Patient attitudinal behavioral factors associated with warfarin non-adherence at outpatient anticoagulation clinics. Int J Behav Med. 2010;17:33-42.
52. Lummis HL, Sketris IS, Gubitz GJ, et al. Medication persistence rates and factors associated with persistence in patients following stroke: a cohort study. BMC Neurol. 2008;8:25.
53. Vidaillet H, Granada JF, Chyou PH, et al. A populationbased study of mortality among patients with atrial fibrillation or flutter. Am J Med. 2002;113:432-435.
54. Howitt A, Armstrong D. Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. BMJ. 1999;318:1324-1327. (Pubitemid 29219046)
55. Higashi MK, Veenstra DL. Managed care in the genomics era: assessing the cost effectiveness of genetic tests. Am J Manag Care. 2003;9:493-500. (Pubitemid 36949536)
56. Eckman M, Rosand J, Greenberg S, et al. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med. 2009;150:73-83.
57. You J, Tsui K, Wong R, et al. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotypeguided dosing in patients starting warfarin therapy. Clin Pharmacol Ther. 2009;86:540-547.